Delisting riskPopularity #5,384
BioNexus Gene Lab (BGLC)
Distributor of composite-industry chemicals with Malaysian genomic screening and an ASEAN cancer-testing license.
$1.50
vs last close+0.04 (+2.74%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.60% | 14.4K shares | |
|---|---|---|---|
| 3 holders · as of Jun 30, 2026 | |||
| Insiders | 21.40% | 517.4K shares | |
| 5 holders · as of Aug 14, 2026 | |||
| Strategic holders | 16.23% | 392.3K shares | |
| 1 holder · as of Aug 7, 2026 | |||
| Other | 61.77% | 1.49M shares | |
| remainder | |||
2.42M company shares as of Aug 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
13F, as of Jun 30, 2026
3 holders · 14.4K shares · 2 new positions · 2 increased · 1 reduced · 1 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| HRT Financial LP | 14.3K | 0.59% | +14.3Knew | Aug 14, 2026 |
| UBS Group AG | 101 | 0.00% | −130 | Aug 13, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | +1new | Aug 5, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Tan Lee Su-Leng | 11.50% | 338.7K | 13D | Aug 14, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.